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Abstract
Aims To estimate the rate at which people with diabetes and a low risk of foot ulceration change diabetic foot
ulceration risk status over time, and to estimate the rate of ulceration, amputation and death among this population.
Methods We conducted an observational study of 10 421 people with diabetes attending foot screening in an
outpatient setting in NHS Fife, UK, using routinely collected data from a national diabetes register, NHS SCI Diabetes.
We estimated the proportion of people who changed risk status and the cumulative incidence of ulceration, amputation
and death, respectively, among people with diabetes at low risk of diabetic foot ulceration at 2-year follow-up.
Results At 2-year follow-up, 5.1% (95% CI 4.7, 5.6) of people with diabetes classified as low risk at their first visit had
progressed to moderate risk. The cumulative incidence of ulceration, amputation and death was 0.4% (95% CI 0.3, 0.6),
0.1% (95% CI 0.1, 0.2) and 3.4% (95% CI 3.1, 3.8), respectively.
Conclusions At 2-year follow-up, 5% of people at low risk of diabetic foot ulceration changed clinical risk status and
<1% of people experienced foot ulceration or amputation. These findings provide information which will help to inform
the current debate regarding optimal foot screening intervals.
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Introduction
It has been estimated that between 15% and 34% of people
with diabetes will experience foot ulceration during their
lifetime, with more than half of those acquiring an infection
that may result in lower extremity amputation and prema-
ture death [1]. These events can result in devastating
consequences for those affected and high costs to the
healthcare system [2].
A cornerstone in the delivery of preventative foot care for
people with diabetes is regular foot screening to identify those
likely to develop foot ulcers, and thus thosemost likely to benefit
from podiatry [3–5]. Recent reviews highlight inconsistent
recommendations in different clinical guidelines, and a low level
of evidence for approaches to foot screening [4,6], in particular
the frequency ofmonitoring [7] and the lackof formalvalidation
in predictive studies [8,9]. The optimal monitoring frequencies
are based on clinical consensus, rather than being evidence-
based.Despite this absenceof evidence, theNational Institute for
Health and Care Excellence (NICE) [3], the Scottish Intercol-
legiate Guideline Network (SIGN) [4] (both in the UK) and the
International Working Group for the Diabetic Foot (IWGDF)
[5] all recommend that foot risk screening is performed annually
for people with diabetes. More frequent foot assessments and
treatments are advised for people with high risk of foot
ulceration, with the monitoring intervals ranging from once
weekly to 6-monthly [3]. An evidenced-based approach to foot
screening could lead to the better use of scarce resources and
more effective care globally.
The aim of the present study was to estimate the rate at
which people with diabetes and a low risk of foot ulceration,
who are attending foot screening in one Scottish Health
Board in the UK, change diabetic foot ulceration risk status
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over time. We also sought to estimate the cumulative
incidence of ulceration, amputation and death, respectively,
among this population.
Methods
Scottish Care Information – Diabetes dataset and study
population
Scottish Care Information – Diabetes (SCI-Diabetes) is a
computerized decision support system used to record clinical
data electronically for everyone with a diagnosis of diabetes in
Scotland [10]. After obtaining approvals from NHS Informa-
tion Governance and R&D, a dataset containing anonymized
data from 26 928 individuals who had received a diagnosis of
diabetes and who attended dedicated foot screening clinics in a
hospital outpatient clinic, primary care or other community
setting in Fife between 2005 and 2017 were obtained. This is
consistent with the reported rate of 50% of the diabetes
populationwho received foot screening in Fife [11]. Death data
from the National Registry of Scotland were linked with the
NHS Fife SCI Diabetes foot data by the Health Informatics
Centre at the University of Dundee.
We included in our analysis only people with diabetes who
had their first visit to a foot screening clinic after 1 March
2009, as death data were unavailable prior to this date. The
dataset included 10 421 people between 2009 and 2017
(Fig. 1).
As the NHS Fife SCI-Diabetes database was used in
routine practice, rather than for research purposes, we
anticipated missing data [12]. To determine the most likely
mechanism for occurrence of missing data, regression
modelling was used to investigate the association between
patient demographics and missingness. Population charac-
teristics were found to be related to ’missingness’, ruling out
the use of multiple imputation techniques [13]. In consulta-
tion with clinical colleagues, a set of decision rules was
created to allow the analysis of these data (see Supporting
information).
Risk factors and clinical outcomes
Three risk factors were used to determine risk of ulceration
in people with diabetes in our study; insensitivity to 10-g
monofilaments at any site on either foot, absent pedal pulses
(specifically, absent dorsalis pedis or posterior tibial pulses
on either foot), and previous history of foot ulceration (all
binary variables). These risk factors are recommended by
NICE, SIGN and IWGDF guidelines. The predicted proba-
bilities of ulceration are based on the prediction of diabetic
foot ulcerations (PODUS) clinical prediction rule (CPR) [14].
A person with diabetes is defined as at low risk of ulceration
if they are sensitive to 10-g monofilaments, have present
pedal pulses, and no history of ulceration.
The clinical outcomes were ulceration, amputation and
death. Ulceration was recorded in the SCI-Diabetes database
as an ’active ulcer’ on either the left or right foot. Incident
primary and new recurrent foot ulcers were recorded as
binary outcomes (present/absent), defined variously includ-
ing ’a full thickness skin defect that requires more than 14
days to heal’ [15]. Minor and major amputation was
recorded in the SCI-Diabetes database as ’lower limb
amputation’ of either left or right foot.
Outcomes were assessed and recorded in the SCI-Diabetes
database during routine visits at foot screening clinics in Fife.
The total number of ulcerations and amputations refers to
the number of people with diabetes who were recorded as
experiencing an ulceration or amputation, not the total
number of ulcerations or amputations. All clinical outcomes,
apart from death, were extracted from the NHS Fife SCI-
Diabetes dataset.
The primary clinical outcomes measured in this study were
the rate of change from low to moderate risk and the
cumulative incidence of ulceration, amputation and death,
respectively, at 2-year follow-up. Follow-up time per patient
was estimated based on the record of the date of first visit to a
foot screening clinic until the date of first occurrence date of an
ulceration, amputation, death, and the change from low to
moderate risk status, respectively, in the SCI-Diabetes dataset.
Analysis
Descriptive statistics for the study population and the
number of foot screening visits are presented in Table 1.
We also provided the number of person-years, number of
total events over the study period, and crude incidence rate of
ulceration, amputation and death, respectively, per 1000
person-years.
We explored whether people at low risk of foot ulceration
changed their risk status over time, in terms of crude
incidence rates (per 1000 person-years) for changing risk
status over time, and the cumulative incidence of changing
from low to moderate risk status over time.
Using a Cox regression framework, we estimated the
relationship between risk of ulceration, amputation and death
What’s new?
• People with diabetes are at increased risk of foot
ulceration. However, there is no evidence regarding the
rate at which people at low risk of diabetic foot
ulceration change risk status over time.
• This study found that people with diabetes who are at a
low risk of foot ulceration do not readily change
ulceration risk status over time (5% at 2 years). The
cumulative incidence of ulceration and amputation,
respectively, at 2 years was <1%.
• This has implications for current guidelines on the
frequency of foot screening in the UK.
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and a person’s age at baseline, sex and the Scottish Index of
Multiple Deprivation (SIMD) [16] in the study population.
We used a competing risk framework to estimate the
cumulative incidence of foot ulceration, amputation and
death, respectively, in a low risk cohort of people with
diabetes who attended a foot screening clinic. To fully assess
the risk of death in this cohort, we usedKaplan–Meier survival
plots to estimate survival after ulceration and amputation. All
analyses were conducted in STATA 14.2 (StataCorp). A statis-
tical significance level of 5% was used throughout.
Ethics
Ethical approval was obtained from Scotland Research
Ethics Committee (REC reference:16/SS/0213/AM01) and
the Information Governance Advisor eHealth, Data Protec-
tion Office NHS Fife.
Results
Study population statistics, screening visits and incidence
rate of ulceration, amputation and death
A total of 10 421 people with diabetes were included, over
a median [interquartile range (IQR)] follow-up of 4.98
Remove patients with no 
follow-up, i.e. death occurs on 
first date
Patients: n = 1,564
Deaths (NRS) (from 2005)
Patients: n = 6,817
Additional patients: n = 68
NHS Fife SCI Diabetes & 
Deaths (NRS) 
Patients: n = 10,421
Remove patients whose first 
appointment was prior to 
March 1st 2009
Patients: n = 15,011
NHS Fife SCI Diabetes & 
Deaths (NRS) 
Patients: n = 26,996
NHS Fife SCI Diabetes & 
Deaths (NRS) 
Patients: n = 25,432
NHS Fife SCI Diabetes 
(from 2005)
Patients: n = 26,928
FIGURE 1 Cohort identification from NHS Fife SCI Diabetes dataset. NRS (National Records of Scotland).
Table 1 Descriptive statistics of the population at baseline (N = 10
421)
Median follow-up time, years 4.98
Mean (SD) age, years 64 (15)
Men, n (%) 4736 (45)
Women, n (%) 5685 (55)
Ulcerations, n (%) 106 (1)
Amputations, n (%) 42 (0.4)
Deaths, n (%) 1178 (11)
Low risk at first visit, n (%) 9614 (92)
Moderate risk at first visit, n (%) 793 (8)
High risk at first visit, n (%) 14 (<1)
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(3.29–6.77) years. The mean age of the population was 64
years and 45% were men. Of these, approximately 1%
developed an ulcer, 0.4% required an amputation, and 11%
died during the follow-up period. Overall 92% were low
risk, 8% moderate risk and <1% high risk at baseline.
The median (IQR) number of clinic visits was 5 (3–7), with
almost 80% having more than one foot examination and,
846 of people (8%) had >10 visits. The median (IQR) time
between the first and second visit was 1.1 (0.9–1.6) years,
and the median (IQR) time between first and last visit was
3.1 (1.8–4.7) years (see Supporting information).
The number of person-years and crude incidence rate, per
1000 person-years, for ulceration, amputation and death,
respectively, among people categorized as low risk can be
found in Table 2.
A total of 75 ulcerations were recorded in people who had
a low risk of diabetes at baseline, 67 (89%) of those occurred
in people who had five or more foot screening visits. A total
of 36 amputations occurred, with 33 (92%) in people who
had five or more foot screening visits. A total of 969 deaths
occurred, with 490 (51%) in people with five or more foot
screening visits.
Change in risk status over time for those at low risk
The person-years and crude incidence rates for transition
from low to moderate risk for those people who changed risk
status, are given in Table 3. We observed a higher rate of
transition to moderate risk between years 1 and 2. The rate
of transition from low to moderate risk decreased over time.
The proportion of the low-risk population which changed
risk status over time was estimated as the cumulative
incidence of changing from low to moderate risk status. At
2-year follow-up, 5.1% (95% CI 4.7, 5.6) of people classified
as low risk at their first visit had progressed to moderate risk
(Fig. 2).
Cox regression analysis
Age was statistically significantly associated with an
increased risk of ulceration [HZ: 1.05 (95% CI 1.03,
1.07)], amputation [1.03 (95% CI 1.00, 1.06)] and death
[1.07 (95% CI 1.06, 1.07)]. Male sex was statistically
significantly associated with an increased risk of death
[hazard ratio 1.14 (95% CI 1.00, 1.30)], however, it was
not found to be statistically significantly associated with
ulceration or amputation. SIMD data were not significantly
associated with outcomes (see Supporting information).
Cumulative incidence of ulceration, amputation and death
At 2-year follow-up, the cumulative incidence of ulcer,
amputation and death among the low risk cohort of people
with diabetes was 0.4% (95% CI 0.3, 0.6), 0.1% (95% CI
0.1, 0.2) and 3.4% (95% CI 3.1, 3.8), respectively (Fig. 3).
At 2 years after ulceration, 5% of this population had died
(Fig. 4). At 2 years after amputation, 7% of this population
had died. For both ulceration and amputation, approxi-
mately 50% of people with diabetes had died after 8 years.
Discussion
This is the first reported analysis of the probability of
transitioning from baseline low foot ulceration risk to
moderate or high risk. Understanding the rate at which
people with diabetes change foot risk status is important in
determining how often people with diabetes require screen-
ing. If people with diabetes change risk status infrequently,
then regular foot screening is less likely to be of clinical
value. These results suggest that people with diabetes change
from low foot risk status slowly, with 5.1%, 9.9% and
11.3% changing risk status at 2, 5 and 8 years follow-up,
respectively. For people who had been low risk for the first 2
years after diagnosis, the rates of progression at 2 and 5 years
were 3.9% and 6.5%. The main reason for a change from
low to moderate risk status was due to the development of
neuropathy (94% of people developed an insensate foot,
Table 2 Person-time and incidence rates* of ulceration, amputation
and death (per 1000)
Person-
years
Number of
events
Rate per 1000
(95% CI)
Ulceration 48 379 75 1.55 (1.24, 1.94)
Amputation 51 361 36 0.70 (0.51, 0.97)
Death 48 623 969 19.93 (18.71,
21.22)
Note. that these incidence rates are based on total number of
events, and do not account for competing risks, i.e. the change
in probability of experiencing an event based on having first
experienced a ’competing’ event.
Table 3 Person-time and incidence rates of transition from low to
moderate risk status (per 1000)
Time
period
Cohort person-
time Events Rate (95% CI)
0–1 year 9478 172 18.14 (15.62,
21.07)
1–2 years 8991 313 34.81 (31.16,
38.88)
2–3 years 7805 180 23.06 (19.92,
26.69)
3–4 years 6353 114 17.94 (14.93,
21.55)
4–5 years 4947 51 10.30 (7.83, 13.56)
5–6 years 3655 43 11.76 (8.72, 15.86)
6–7 years 2372 11 4.63 (2.56, 8.37)
7–8 years 1275 0 0
>8 years 359 0 0
Total 45 235 884 19.54 (18.29,
20.87)
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whilst only 7% developed absent pulses). These data provide
information regarding the rate of progression of foot risk and
may raise issues about the desirable frequency of foot
screening for people at a low risk of foot ulceration. A
cohort study of diabetes-related complications in those newly
diagnosed with diabetes also reported that the rate of
peripheral neuropathy greatly reduced after 6 years [17].
As virtually no people with diabetes transitioned from low to
high foot risk status, which is where the main concern
regarding ulceration exists, extending the screening interval
may be indicated. Longer monitoring intervals would allow a
more effective allocation of scarce health resources among
diabetes healthcare professionals, such as preventative inter-
ventions [18]. A similar approach to examining the optimal
screening intervals in diabetic retinal screening is currently
underway [19].
As expected, 2-year outcomes in people with diabetes at
high risk of diabetic foot ulcers were worse [1] than those of
our low-risk cohort for amputation rates (1.6% vs 0.1%)
and death rates (15% vs 3.4%). In a previous study of 3526
people with diabetes with 1.7 years’ follow-up, the ulceration
rate was 0.36% and the death rate identical to ours at 3.4%
in low-risk people with diabetes [20].
The mortality rate among people with diabetes, who were
classified as low risk at first visits but who subsequently
developed a foot ulcer or received an amputation, was
approximately 30% at 5-year follow-up. This is comparable
with previous research [21–24]. Foot ulceration is well
0%
2%
4%
6%
8%
10%
12%
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
People who move from low to moderate risk anytime
People who move from low to moderate risk after 2 years
FIGURE 2 Cumulative incidence of change from low to moderate risk for all people with diabetes and for only people with diabetes who remained at
low risk after 2 years, respectively.
FIGURE 3 Cumulative incidence plot of ulceration, amputation and death (low-risk cohort only). Time 0 refers to the person’s first visit to a foot
screening clinic.
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recognized as being associated with increased mortality
[25,26], but a foot classification of high risk may be a
greater risk than having an active ulcer for mortality [1].
The median (IQR) number of foot screening visits over the
study period was 5 (3–7), corresponding to an approximate
annual screen over 5 years’ follow-up. As expected, the
mortality rate at 2 years of 3.4% for people with diabetes at
low risk of ulceration is similar to the mortality rate of 3.6%
for all people with diabetes in Fife. Our classification of risk
was based on the predicted probabilities of foot ulcer from
the PODUS clinical prediction rule [9]. These predicted
probabilities are based on an individual’s response to
monofilaments, pedal pulse testing and previous history of
ulceration; however, we acknowledge that these are not the
only means by which risk can be assessed for diabetic foot
ulceration in people with diabetes and that additional risk
factors are recommended for consideration in clinical guide-
lines and the published literature [3,4,27,28].
The NHS Fife SCI Diabetes dataset was obtained from
routine clinical practice and hence gives an insight into
patient outcomes in a ’real-world’ setting. The baseline data
were collected by a wide range of individuals and, because
these data were not collected for research purposes, there
may be some inconsistencies in recording relating to the
healthcare system. There are missing data, particularly for
clinical prediction rule test results. This introduced uncer-
tainty into our analysis and our findings should be
interpreted cautiously. The amputation events may also have
been be under-captured and under-recorded. Data relating to
the type of ulceration or amputation were not provided in
SCI-Diabetes. Hence, we are unable to distinguish between
minor or major ulceration or amputation events, a distinc-
tion which is highly relevant from a clinical and patient
perspective.
According to the Scottish Diabetes Survey 2018 [11], the
foot ulcer incidence (1.7% for type 1 diabetes and 0.9% for
type 2 diabetes) and prevalence (2.7% for type 1 diabetes
and 1.4% for type 2 diabetes) in Fife is very similar to that of
Scotland as a whole (type 1 diabetes: incidence 1.7% and
prevalence 2.8%, and type 2 diabetes: incidence 0.9% and
prevalence 1.4%), which means that our data are likely to be
generalizable. Furthermore, the mortality rate within the
previous year, for the people with diabetes was 3.6% for
Fife, compared with 3.7% for Scotland as a whole. These
figures suggest that Fife is reasonably representative of the
epidemiology of the general diabetes population in Scotland.
Further research to understand who attends foot screening,
the nature of advice, preventative care or treatment if any is
provided, and the uniformity of care across clinics nationally
is warranted. The question of how often to perform foot
screening needs addressing.
In conclusion, in the present study, we sought to estimate the
rate of complications amongpeoplewith diabetes and a low risk
of foot ulceration who were attending routine foot screening.
FIGURE 4 Time to event (1- Kaplan–Meier) plots for time to death following ulceration and amputation, respectively (low-risk cohort only). Time 0
refers to the person’s first visit to a foot screening clinic.
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Five percent of people with diabetes who were at a low risk of
foot ulceration progressed to moderate risk in 2 years. In
addition, we found that the cumulative incidence of ulceration
and amputation at 2 years was <1%. This raises the question of
the ideal frequency for foot screening, andwhether less frequent
screening of people with low-risk feet would be effective and
safe. This may have implications for current guidelines on the
frequency of foot screening in the UK.
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